Analyst Price Target is $6.00
▲ +66,566.67% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Better Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $9.00 and a low forecast of $3.00. The average price target represents a 66,566.67% upside from the last price of $0.01.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Better Therapeutics. This Buy consensus rating has held steady for over two years.
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Read More
